Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 206-792-6 | CAS number: 375-72-4
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Repeated dose toxicity: inhalation
Administrative data
- Endpoint:
- sub-chronic toxicity: inhalation
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 26 October- 30 January 2001
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: Study was conducted under GLP conditions
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 001
- Report date:
- 2001
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 412 (Subacute Inhalation Toxicity: 28-Day Study)
- GLP compliance:
- yes
Test material
- Reference substance name:
- T-7499
- IUPAC Name:
- T-7499
- Details on test material:
- - Name of test material (as cited in study report: T-7499; Perflurobutyl sulfonyl fluoride
- Physical state: Clear colorless liquid
- Analytical purity: 96-98 % Perfluorobutyl sulfonyl fluroide; 2-4% Perfluorosulfolane
- Lot/batch no.: None stated
- Expiration date of the lot/batch: None stated
- Stability under test conditions: stable
- Storage condition of test material: Ambient temperature or in a refrigerator, unless otherwise stated by the sponsor.
Constituent 1
Test animals
- Species:
- rat
- Strain:
- other: Crl:CD BR Sprague-Dawley
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River (UK) Limited, Manston Road Margate, Kent.
- Age at study initiation: approximately 6 weeks
- Weight at study initiation: 163-293g
- Housing: 5 animals of the same sex in suspended stainless steel cage fitted with mesh front, back and floor with stainless steel sheet sides. Exposure occured in the same room animals were housed.
- Diet (e.g. ad libitum): ad libitum (to a weighed amount of quality control food)
- Water (e.g. ad libitum): ad libitum
- Acclimation period: at least 7 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C):19.5-21.0 degrees C
- Humidity (%):39-58%
- Photoperiod (hrs dark / hrs light): 12 hours light/12 hours dark
IN-LIFE DATES: From: 13 November To: 30 January 2001
Administration / exposure
- Route of administration:
- inhalation: vapour
- Type of inhalation exposure:
- whole body
- Vehicle:
- other: Unchanged (no vehicle) : clean air used as a diluent
- Details on inhalation exposure:
- GENERATION OF TEST ATMOSPHERE / CHAMBER DESCRIPTION
- Exposure apparatus: vapor genarator
- System of generating particulates/aerosols: produced by metering the test liquid into stainless steel coil vapour generators and was diluted with clean air prior to the resultant vapour atmosphere passing into the exposure chamber.
- Temperature, humidity, pressure in air chamber: Temperature in chamber was 21-22 degrees C. Chamber pressure was -2 to -4 mm water. Relative humidity was 19-32%
- Air flow rate: 150 l/min (100 l/min diluent air and 50 l/min test substance)
- Treatment of exhaust air: vented to an exhaust stack
VEHICLE (if applicable)
- Justification for use and choice of vehicle: diluent air - Duration of treatment / exposure:
- 6 hour exposure
- Frequency of treatment:
- 5 consecutive days of each week for 4 weeks
Doses / concentrations
- Remarks:
- Doses / Concentrations:
0 (control), 50 ppm, 150 ppm and 450 ppm (study mean exposure levels were 47, 162 and 459 ppm).
Basis:
nominal conc.
- Control animals:
- other: Yes, exposed to diluent air to the same methods the exposed groups
- Details on study design:
- - Dose selection rationale: after discussion with sponsor and the review of available data
Examinations
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: cages were checked for mortality in the morning and at the end of the normal working day.
- Cage side observations included observations of dead or moribund animals.
DETAILED CLINICAL OBSERVATIONS: Yes
BODY WEIGHT: Yes
- Time schedule for examinations: weekly, commencing 1 week prior to the start of exposures and when any possibly significant observations were made during daily checks or at anytime during the study.
FOOD CONSUMPTION AND COMPOUND INTAKE (if feeding study):
- Food consumption for each animal determined and mean daily diet consumption calculated as g food/kg body weight/day: No, this is not a feeding study, but food consumption is calculated as group mean values as grams/animal.
- Compound intake calculated as time-weighted averages from the consumption and body weight gain data: No
FOOD EFFICIENCY:
- Body weight gain in kg/food consumption in kg per unit time X 100 calculated as time-weighted averages from the consumption and body weight gain data: No data
WATER CONSUMPTION AND COMPOUND INTAKE (if drinking water study): No data
HAEMATOLOGY: Yes
- Time schedule for collection of blood: week 4 of exposure
- Anaesthetic used for blood collection: No data
- How many animals: all animals
- Parameters checked in table [No. 1] were examined.
CLINICAL CHEMISTRY: Yes
- Parameters checked in table [No.2] were examined.
URINALYSIS: No
- Parameters checked in table [No.2] were examined.
NEUROBEHAVIOURAL EXAMINATION: Yes
- Time schedule for examinations: a full functional observation battery was performed during the pre-treatment period and during week 4. A shortened batery was performed during weeks 1, 2, and 3.
- Dose groups that were examined: All dose groups were tested.
- Battery of functions tested: Observations in the hand: ease of removing animal from cage, reactivitiy to handling, occurence of convulsions, tremors, twitches, salivation/lacrimation, palpebral closure, exophthalmus, piloerection, fur appeance, vocalisation on handling;
Observations in the arena: occurrence of convulsions, tremors, twitches, activity counts, level of arousal, rearing count, grooming, piloerection, assessment of gait/posture, record presence of fecal boluses, urine; Manipulations: approach response, touch response, auditory startle response, righting reflex, tail pinch response, pupil reflex, grip strength (fore and hindlimb), landing footsplay, body temperature and bodyweight. - Sacrifice and pathology:
- GROSS PATHOLOGY: Yes (see table 3)
HISTOPATHOLOGY: Yes (see table 4)
Results and discussion
Results of examinations
- Clinical signs:
- effects observed, treatment-related
- Mortality:
- mortality observed, treatment-related
- Body weight and weight changes:
- effects observed, treatment-related
- Food consumption and compound intake (if feeding study):
- no effects observed
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- no effects observed
- Clinical biochemistry findings:
- no effects observed
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- effects observed, treatment-related
- Organ weight findings including organ / body weight ratios:
- no effects observed
- Gross pathological findings:
- no effects observed
- Histopathological findings: non-neoplastic:
- no effects observed
- Details on results:
- CLINICAL SIGNS AND MORTALITY: There were no unscheduled deaths. Clinical signs observed as a group response during exposure included vocalising and agitation when handled for Groups 2, 3, and 4. Walking on toes (abnormal gait) was evident following the exposures for Groups 3 and 4. Hyperactivity was observed following the exposures for Groups 3 and 4 during weeks 2 and 3. This sign was also evident following the exposures for Group 2 rats during Week 3. On three occasions, signs were present prior to exposure. Agitation when handled was present for a Group 3 female rat prior to exposure on Day 17. Vocalising and agitation when handled were present for two Group 3 female rats prior to exposure on Day 19. Walking on toes (abnormal gait) was present for Group 4 female rats prior to exposure on Day 26. At all ofther times, all of the above signs had resolved prior to exposure the following day. At other times, dry skin abrasions to tails, irritable behaviour and pale coloured teeth were observed. These signs are considered incidental and not related to treatment.
BODY WEIGHT AND WEIGHT GAIN: The overall mean bodyweight gains for all test rats (weeks 0 to 4) were lower than controls, attaining a degree of statistical significance for all test males.
FOOD CONSUMPTION AND COMPOUND INTAKE (if feeding study): This study was not a feeding study, but a reduction in food consumption was evident for Group 4 male rats. The food consuption of other test rats was considered not to be affected by treatment.
FOOD EFFICIENCY
WATER CONSUMPTION AND COMPOUND INTAKE (if drinking water study)
OPHTHALMOSCOPIC EXAMINATION
HAEMATOLOGY: No treatment related findings.
CLINICAL CHEMISTRYL: No treatment related effects
URINALYSIS
NEUROBEHAVIOUR: Functional observational battery findings for animals treated with the test article showed no evidence of neurotoxicity. In the hand observations were unaffected by treatment. Arena observations showed some inter-group variation but the differences were not considered to be treatment-related. Compared with controls, females in all treated groups showed reduced activity and rearing scores in the arena during week 3 of treatment, although scores for males were unaffected. In the absence of similar response patterns during, preceding, or subsequent weeks of treatment, these differences were considered to be due to natural variation. During week 4 of treatment, landing footsplay measurements for females receiving 150 or 450 ppm were lower than those of controls. Mean values for these groups were therefore not considered to be associated with treatment. The time spent in locomotor activity for males recieving 150 ppm was lower than that shown by control animals during Week 4 of treatment whereas, in contrast, females receiving 50 or 150 ppm showed increased activity times. These differences failed to achieve statistical significance and, in view of the lack of dosage-relationship and the opposing directions of change, were considered to be due to natural variation.
ORGAN WEIGHTS: No treatment related findings
GROSS PATHOLOGY: No treatment related findings.
HISTOPATHOLOGY: NON-NEOPLASTIC: No treatment related findings
Effect levels
- Dose descriptor:
- other: a No Observed Effect Level (NOEL) was not able to be established during this study.
- Sex:
- male/female
- Basis for effect level:
- other: see 'Remark'
- Remarks on result:
- not measured/tested
- Remarks:
- Effect level not specified (migrated information)
Target system / organ toxicity
- Critical effects observed:
- not specified
Applicant's summary and conclusion
- Conclusions:
- A no observed effect level was not established during this study. However, clinical signs consistent with a transient effect on nervous system had generally resolved prior to exposure the following day and there was no evidence of sustained neurotoxicity in the functional observation battery.
- Executive summary:
Three groups (each of 5 males and 5 females) of the Crl: CD BR Sprague-Dawley strain were exposed to the test article for 6 hours a day for 5 consecutive days a week for 4 weeks using a whole-body exposure system. A fourth group, acting a control, was exposed to air only. The study mean analyzed concentrations of the test articles were 47, 162 and 459 ppm for the Low, Intermediate and High dose groups respectively. Clinical signs observed during exposure included circling movement and lethargy. Clinical signs observed immediately post exposure included vocalizing and agitation when handled, walking on toes (abnormal gait) and hyperactivity. These signs were consistent with a neurotoxic effect and generally resolved prior to exposure the following day. The overall mean bodyweight gains for all test rats (Weeks 0 to 4) were lower than controls, attaining a degree of statistical significance for all test males. A reduction in food consumption was evident for Group 4 male rats. There was no effect of treatment on the functional observational battery of haemotological and blood chemistry parameters. Necropsy revealed no treatment-related macroscopic findings and no treatment-related differences in organ weights. Histopathological examination of the respiratory tract revealed no treatment-related findings. A no observed effect level was not established during this study. However, clinical signs consistent with a transient effect on nervous system had generally resolved prior to exposure the following day and there was no evidence of sustained neurotoxicity in the functional observation battery.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.